When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Before Wegovy, 190,000 people in the U.S. were claiming GLP-1 ... with 5.1 percent of white patients with obesity on weight loss drugs compared to just 3.7 percent of Hispanic patients with obesity.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

While plenty of people rave about the weight loss results you can get from drugs like Ozempic, there’s also been a ton of ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

People who have obesity regularly report medical providers are rude or dismissive toward them, research shows, which can lead ...